Quarterly report pursuant to Section 13 or 15(d)

Selected Balance Sheet Data

v3.23.1
Selected Balance Sheet Data
9 Months Ended
Mar. 31, 2023
Notes to Financial Statements  
Selected Balance Sheet Data

Note 3. Selected Balance Sheet Data:

Inventories:

Inventories consist of (in thousands):

    

March 31, 

June 30, 

    

2023

    

2022

Raw materials

$

87,006

$

79,291

Finished goods(1)

 

88,038

 

66,943

Inventories, net

$

175,044

$

146,234

(1) Finished goods inventory of $5,580 and $5,111 included within other long-term assets in the respective March 31, 2023 and June 30, 2022, consolidated balance sheet. The inventory is included in long-term assets as it is forecasted to be sold after the 12 months subsequent to the consolidated balance sheet date.

Property and Equipment:

Property and equipment consist of (in thousands):

    

March 31, 

June 30, 

    

2023

    

2022

Land

$

9,080

$

8,572

Buildings and improvements

 

242,958

 

229,551

Machinery and equipment

190,896

174,813

Construction in progress

 

11,065

 

21,729

Property and equipment, cost

 

453,999

 

434,665

Accumulated depreciation and amortization

 

(230,428)

 

(211,423)

Property and equipment, net

$

223,571

$

223,242

Intangible Assets:

Intangible assets consist of (in thousands):

March 31, 

June 30, 

2023

2022

Developed technology

$

615,752

$

542,038

Trade names

 

146,781

 

146,457

Customer relationships

 

224,626

 

225,882

Patents

 

3,716

 

3,313

Other intangibles

 

11,560

 

6,306

Definite-lived intangible assets

 

1,002,435

 

923,996

Accumulated amortization

 

(471,878)

 

(415,174)

Definite-lived intangibles assets, net

 

530,557

 

508,822

In process research and development

 

22,700

 

22,700

Total intangible assets, net

$

553,257

$

531,522

Changes to the carrying amount of net intangible assets for the period ended March 31, 2023 consist of (in thousands):

Beginning balance

$

531,522

Acquisitions

 

75,600

Other additions1)

 

5,596

Amortization expense

 

(58,400)

Currency translation

(1,061)

Ending balance

$

553,257

1) Includes the purchase of a $4.6 million intangible asset from Wilson Wolf, an equity method investee of the Company, during the quarter ended March 31, 2023. This asset will be amortized over a life of 10 years.

The estimated future amortization expense for intangible assets as of March 31, 2023 is as follows (in thousands):

Remainder 2023

    

$

19,190

2024

 

75,232

2025

 

71,958

2026

 

67,986

2027

 

57,824

Thereafter

 

238,367

Total

$

530,557

Goodwill:

Changes to the carrying amount of goodwill for the period ended March 31, 2023 consist of (in thousands):

    

    

Diagnostics and

    

Protein Sciences

 Genomics

Total

June 30, 2022

$

376,493

$

445,608

$

822,101

Acquisitions

 

51,051

-

51,051

Currency translation

 

(2,710)

100

(2,610)

March 31, 2023

$

424,834

$

445,708

$

870,542

We evaluate the carrying value of goodwill in the fourth quarter of each fiscal year and between annual evaluations if events occur or circumstances change that would indicate a possible impairment. The Company performed a quantitative goodwill impairment assessment for all of its reporting units during the fourth quarter of fiscal 2022. No indicators of impairment were identified as part of our assessment.

Other Assets:

Other assets consist of (in thousands):

    

March 31, 

June 30, 

    

2023

    

2022

Equity method investments

$

257,000

$

Other

 

26,354

 

46,828

Other assets

$

283,354

$

46,828